Literature DB >> 16708368

Value of repeated measures of nerve conduction and quantitative sensory testing in a diabetic neuropathy trial.

Shawn J Bird1, Mark J Brown, Cathie Spino, Sharon Watling, Howard L Foyt.   

Abstract

Conduct of a large, multicenter trial of the aldose reductase inhibitor zenarestat provided data on the reproducibility of multiple electrophysiologic (nerve conduction studies, NCS) and quantitative sensory (QST) tests. Baseline and 12-month electrophysiologic data from approximately 1100 patients at multiple centers were available for analysis. Intersite variability contributed minimally to overall test variance. All NCS tests were highly reproducible. Cool thermal and vibration QST thresholds, as measured by CASE IV instrumentation, were also highly reproducible. Intersubject variance accounted for the majority of variance for all parameters measured. Repeating NCS and QST measures decreased sample sizes needed to show statistical significance. Consideration of these observations, particularly with regard to QST, should aid in the design of future clinical trials investigating neuropathy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16708368     DOI: 10.1002/mus.20577

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  12 in total

1.  Thermal perception thresholds among young adults exposed to hand-transmitted vibration.

Authors:  T Nilsson; L Burström; M Hagberg; R Lundström
Journal:  Int Arch Occup Environ Health       Date:  2008-01-05       Impact factor: 3.015

2.  Reliability of quantitative sudomotor axon reflex testing and quantitative sensory testing in neuropathy of impaired glucose regulation.

Authors:  Amanda Peltier; A Gordon Smith; James W Russell; Kiran Sheikh; Billie Bixby; James Howard; Jonathan Goldstein; Yanna Song; Lily Wang; Eva L Feldman; J Robinson Singleton
Journal:  Muscle Nerve       Date:  2009-04       Impact factor: 3.217

3.  Reliability of the method of levels for determining cutaneous temperature sensitivity.

Authors:  Miroljub Jakovljević; Igor B Mekjavić
Journal:  Int J Biometeorol       Date:  2011-08-21       Impact factor: 3.787

Review 4.  Mobility-Related Consequences of Reduced Lower-Extremity Peripheral Nerve Function with Age: A Systematic Review.

Authors:  Rachel E Ward; Paolo Caserotti; Jane A Cauley; Robert M Boudreau; Bret H Goodpaster; Aaron I Vinik; Anne B Newman; Elsa S Strotmeyer
Journal:  Aging Dis       Date:  2015-11-27       Impact factor: 6.745

5.  Reproducibility of peroneal motor nerve conduction measurement in older adults.

Authors:  Rachel E Ward; Robert M Boudreau; Aaron I Vinik; Sasa A Zivkovic; Omer T Njajou; Suzanne Satterfield; Tamara B Harris; Anne B Newman; Elsa S Strotmeyer
Journal:  Clin Neurophysiol       Date:  2012-09-26       Impact factor: 3.708

6.  Agreement between clinical screening procedures for neuropathy in the feet.

Authors:  Yi Wang; Jaclyn M Goodrich; Robert Werner; Brenda Gillespie; Niladri Basu; Alfred Franzblau
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

Review 7.  Chemotherapy-induced peripheral neurotoxicity.

Authors:  Guido Cavaletti; Paola Marmiroli
Journal:  Nat Rev Neurol       Date:  2010-11-09       Impact factor: 42.937

8.  Utilization of nerve conduction studies for the diagnosis of polyneuropathy in patients with diabetes: a retrospective analysis of a large patient series.

Authors:  Xuan Kong; Eugene A Lesser; Frisso A Potts; Shai N Gozani
Journal:  J Diabetes Sci Technol       Date:  2008-03

9.  Repeatability of nerve conduction measurements derived entirely by computer methods.

Authors:  Xuan Kong; Eugene A Lesser; Shai N Gozani
Journal:  Biomed Eng Online       Date:  2009-11-06       Impact factor: 2.819

10.  Determination of efficacy of reflexology in managing patients with diabetic neuropathy: a randomized controlled clinical trial.

Authors:  Krishna Dalal; V Bharathi Maran; Ravindra M Pandey; Manjari Tripathi
Journal:  Evid Based Complement Alternat Med       Date:  2014-01-09       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.